News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
263,442 Results
Type
Article (14052)
Company Profile (283)
Press Release (249107)
Section
Business (79426)
Career Advice (152)
Deals (13212)
Drug Delivery (34)
Drug Development (50377)
Employer Resources (31)
FDA (5698)
Job Trends (5120)
News (144243)
Policy (10022)
Tag
Academia (901)
Alliances (21590)
Alzheimer's disease (783)
Antibody-drug conjugate (ADC) (70)
Approvals (5686)
Artificial intelligence (90)
Bankruptcy (99)
Best Places to Work (4550)
Biotechnology (232)
Breast cancer (123)
Cancer (1040)
Cardiovascular disease (84)
Career advice (132)
CAR-T (86)
Cell therapy (248)
Clinical research (40420)
Collaboration (401)
Compensation (155)
COVID-19 (1019)
C-suite (104)
Cystic fibrosis (72)
Data (1073)
Diabetes (98)
Diagnostics (1245)
Earnings (29084)
Events (47477)
Executive appointments (326)
FDA (6145)
Funding (379)
Gene editing (72)
Gene therapy (187)
GLP-1 (335)
Government (1069)
Healthcare (6560)
Infectious disease (1060)
Inflammatory bowel disease (100)
IPO (7233)
Job creations (859)
Job search strategy (127)
Layoffs (194)
Legal (1381)
Lung cancer (154)
Manufacturing (95)
Medical device (2566)
Medtech (2567)
Mergers & acquisitions (6185)
Metabolic disorders (298)
Neuroscience (1078)
NextGen: Class of 2025 (2013)
Non-profit (851)
Northern California (1243)
Obesity (162)
Opinion (93)
Parkinson's disease (86)
Patents (72)
People (25276)
Phase I (14269)
Phase II (18795)
Phase III (11886)
Pipeline (462)
Postmarket research (852)
Preclinical (5983)
Radiopharmaceuticals (208)
Rare diseases (231)
Real estate (1411)
Regulatory (8380)
Research institute (932)
Series A (75)
Southern California (1115)
Startups (1969)
United States (9847)
Vaccines (177)
Weight loss (94)
Date
Last 7 days (379)
Last 30 days (1564)
Last 365 days (20384)
2025 (1607)
2024 (20554)
2023 (22414)
2022 (26822)
2021 (27806)
2020 (23360)
2019 (16224)
2018 (11739)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10393)
2013 (7484)
2012 (7532)
2011 (7615)
2010 (7429)
Location
Africa (146)
Asia (17041)
Australia (2883)
California (2838)
Canada (895)
China (255)
Colorado (106)
Connecticut (118)
Delaware (65)
Europe (36659)
Florida (320)
Georgia (84)
Illinois (180)
Indiana (69)
Maryland (371)
Massachusetts (2249)
Minnesota (113)
New Jersey (707)
New York (781)
North Carolina (450)
Northern California (1243)
Ohio (91)
Pennsylvania (536)
South America (207)
Southern California (1115)
Texas (316)
Washington State (272)
263,442 Results for "opsis therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics
BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, announced today that it has exercised its option to exclusively license OpCT-001, an induced pluripotent stem cell (iPSC) derived cell therapy candidate for the treatment of primary photoreceptor diseases, from FUJIFILM Cellular Dynamics and Opsis Therapeutics.
January 23, 2024
·
7 min read
Press Releases
Asimov and RevOpsis Therapeutics Sign Licensing Agreement for High Titer Multispecific-Expressing Cell Line
November 19, 2024
·
2 min read
Press Releases
RevOpsis Therapeutics Awarded $1.8M NEI SBIR Grant to Advance R&D for Groundbreaking Ophthalmic Therapies
October 15, 2024
·
3 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Business
BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI) and David Gamm, M.D., Ph.D., co-founder
May 17, 2021
·
10 min read
Press Releases
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
January 30, 2025
·
4 min read
Press Releases
Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference
January 30, 2025
·
1 min read
Press Releases
NeuroEM Therapeutics(R) Accepted into StartUp Health’s Alzheimer’s Moonshot Community(TM)
September 19, 2024
·
4 min read
Press Releases
Elevar Therapeutics Announces the Formation and Members of Scientific Advisory Board
January 27, 2025
·
5 min read
Regulatory
FDA Warns Applied Therapeutics of ‘Objectionable Conditions’ in Govorestat Study
The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical trial—including a dosing error for govorestat—claims that the company said it had already addressed.
December 4, 2024
·
2 min read
·
Tristan Manalac
1 of 26,345
Next
